dr. zelenetz on zanubrutinib research in mcl
Published 4 years ago • 251 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
1:08
dr. song on zanubrutinib activity in relapsed/refractory mcl
-
0:58
dr. leslie on the benefits with zanubrutinib in mcl
-
1:26
dr. patel discusses zanubrutinib in mcl
-
1:22
dr. leslie on sequencing zanubrutinib in mcl
-
1:31
dr. zelenetz on progress made in mcl treatment
-
0:59
dr. rule on the fda approval of zanubrutinib in mcl
-
2:05
dr. zelenetz on potential of acalabrutinib and bgb-3111 in cll
-
1:58
dr. zelenetz on current treatment options for mcl
-
8:42
how lymph cells gain access to brain?
-
53:16
"i. layered identity of b cell memory. ii. unusual specificities of γδtcrs." by dr. taras kreslavsky
-
14:31
teclistamab - guest lecture
-
1:02
dr. tam on zanubrutinib vs ibrutinib research in mantle cell lymphoma
-
1:10
dr. wang on the toxicity of ibrutinib, acalabrutinib, and zanubrutinib in mcl
-
0:44
dr. tam on zanubrutinib approval in mcl
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
1:46
novel agent combinations for cll: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
-
1:42
zanubrutinib plus rituximab in first-line mcl therapy
-
1:03
dr. maddocks on the role of zanubrutinib in b-cell malignancies
-
1:23
dr. rule on the future treatment paradigm in mcl
-
1:13
john burke, md, outlines the patient profile best suited for zanubrutinib in relapsed/refractory mcl
-
2:40
successful use of zanubrutinib for r/r mcl in china
-
5:00
beigene’s brukinsa (zanubrutinib): a newly approved treatment medicine for mantle cell lymphoma (mcl